T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-α, 5- fluorouracil, and vinblastine

Cancer Investigation

Volumn 17, Issue 4, 1999, Pages 259-263

  Gez, Eliahu ^a   Mekori, Tamar ^a   Struminger, Lily ^a   Rubinov, Rafael ^b   Nativ, Ofer ^c   Stein, Avi ^d   Haim, Nissim ^a   Kuten, Abraham ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b Linn Medical Center   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LUNG METASTASIS; MALE; PHENOTYPE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 0032926988     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909040595     Document Type: Article

References (19)

1. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696, 1995.
2. Hofmockel G, Theiss WL, Gruss A, et al: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 156:18-21, 1996.
3. Sella A, Kilbourn RG, Gray I, et al: Phase I study of interleukin-2 combined with interferon-α and 5-fluorouracil in patients with metastatic renal cell carcinoma. Cancer Biother 9:103-111, 1994.
4. Hanninen EL, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155:19-25, 1996.
5. Kaver I, Pecht M, Tranin N, et al: T lymphocyte subpopulation and function in the peripheral blood of patients with urological cancer. Oncology 49:108-113, 1992.
6. Lissoni P, Barni S, Rovell F, et al: Correlation of serum interleukin-2 levels, soluble interleukin-2 receptors and T lymphocyte subpopulation in cancer patients. Tumori 76:14-17, 1990.
7. Dillman RO, Koziol JA, Zavanelli MI, et al: Immunoincompetence in cancer patients. Assessment by in vitro stimulation tests and quantification of lymphocyte subpopulations. Cancer 53: 1484-1491, 1984.
8. Mantovani G, Sern FG: Functional and surface phenotype study of lymphocyte subsets in peripheral blood and lymph nodes of breast cancer patients. Cancer Detect Prevent 13:323-332, 1989.
9. Grups JW, Frohmuller HG: Influence of cyclic interferon gamma on lymphocytes and their subpopulations in patients with renal carcinoma. Urology 35:111-113, 1990.
10. Hernberg M, Muhonen T, Pyrhonen S: Can the CD4+/CD8+ ratio predict the outcome of interferon-α therapy for renal cell carcinoma? Ann Oncol 8:71-77, 1997.
11. Fortis C, Ferrero E, Heltai S, et al: Role of interleukin-2 in regulating lymphocyte activation and recirculation. Eur J Cancer 29A: 474, 1993.
12. Bowen Yacyshn MB, Poppema S, Berg A, et al: CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlation with survival following active specific immunotherapy. Int J Cancer 61:470-474, 1995.
13. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results in cancer treatment. Cancer 47:207-214, 1981.
14. Sprent P: Applied Nonparametric Statistical Methods, London, Chapman and Hall, 1989.
15. Wilcoxon F: Individual comparisons by ranking methods. Biometrics 1:80-83, 1945.
16. Keller JW, McCune CS, Saharabudhe DM: Urologic and male genital cancer. In: Clinical Oncology, 7th ed., edited by P Rubin, Philadelphia, W.B. Saunders, 1993.
17. Pillai R, Balaram P, Nair BS, et al: Lymphocyte subset distribution after radiation therapy for cancer of the uterine cervix. Cancer 67:2071-2078, 1991.
18. Sevcikova L, Hunakova L, et al: T-lymphocyte subsets (CD4/ CD8 ratio) in breast cancer patients. Neoplasma 39:219-222, 1992.
19. Pasukoniene V, Kazlauskaite N, Mauricas M, et al: CD4+ and CD8+ lymphocytes during immunotherapy of renal cell carcinoma patients. Fourth International Symposium on Clinical Immunology, June 1997, Amsterdam (abstract).